The Imminent Change of the Antithrombotics Market
The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio - June 01, 2007
The New Class of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Has One Clear Leader and Many Followers
Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field. - March 05, 2007
TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still No. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4%), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25%). - February 27, 2007
Dosing Convenience is Mandatory to Keep Pace in the Pipeline Race of GLP-1 Analogs for Type 2 Diabetes
The Business Intelligence firm La Merie S.L. reported today that major diabetes companies are trying to keep pace with Eli Lilly and Amylin Pharmaceutical in the field of GLP-1 analogs to treat type 2 diabetes. Lilly’s and Amylin’s first-in-class, but twice-daily product exenatide... - February 06, 2007
Overview on 2006 Sales of Top 20 Biologics to Be Released on February 26
A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26. - February 05, 2007
The Right Balance Drives the Field of PPAR Agonist R&D
A strongly growing market of now more than US$ 6 billion in 2006 for only two PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations. - January 12, 2007
Delivery Improvements of the AMD-drug Lucentis on the Way
The anti-VEGF Fab Lucentis is the new standard of care to treat AMD because it can improve visual acuity. Competitor drugs directed against the same and innovative targets are applied with non-intravitreal forms of administration to avoid the unease of intra-vitreal injection. - September 20, 2006
Biologics Define New Standard of Therapy in Psoriasis
Anti-TNF agents set the new gold standard of psoriasis treatment which could be outperformed by smarter next generation biologics and small molecules in safety and convenience. - September 08, 2006
The Crowded Field of VEGF and VEGF-R Targeting Drugs
The versatility of the vascular endothelial growth factor (VEGF) signalling pathway as a validated target and its excellent tractability explain a crowded field of drugs of all classes. - August 17, 2006
A Full Pipeline of Follow-on TNF-Antagonists
The US$ 7.6 bln market of TNF-antagonists attracts numerous follow-on compounds including improved TNF-antagonists and molecules originating from new technologies. - August 02, 2006
Biogenerics and New Technologies Compete with 1st Generation Major Products
The US$ 32 bln market of six major protein products is enfacing competition by less costly biogenerics and by improved products via drug delivery or protein engineering technologies and even oral, small molecule solutions. - June 20, 2006
Imminent Launches of New EPO Products and Consolidation of the Biogenerics Field
The Business Intelligence firm La Merie S.L. reported today changes in the field of erythropoiesis stimulating agents (ESA) observed in a follow-up analysis. The first launch of a new ESA in Europe is expected to be Shire’s epoetin omega in the first half of 2007 to be followed by... - June 03, 2006
Localized Delivery of PDE-4 Inhibitors to Open the Therapeutic Window
The Localized delivery of phosphodiesterase-4 (PDE-4) inhibitors appears to be short term solution to overcome the dose-limiting side effects of severe nausea and emesis occurring after oral administration. In the long-term, subtype-selective PDE-4 inhibitors and combination regimens may help to improve the therapeutic index. - May 31, 2006
The Next Generation of Interferons Needs Improvement in Efficacy and Safety
The interferon alpha market is smaller than the interferon beta market, but is characterized by far more products and R&D projects. Conversion of the interferon alpha market to pegylated products explains why new R&D is focused on interferon alpha variants or other subtypes with improved pharmacodynamic and safety properties. - May 19, 2006
RNA Interference (RNAi) is Coming of Age as a Therapeutic Modality
The Business Intelligence firm La Merie S.L. reported today that the RNAi therapeutic pipeline is rapidly filling and advancing towards clinical development. Four RNAi therapeutic projects are in early clinical development. At least 32 RNAi projects are in preclinical development in a variety of... - May 10, 2006
Antibodies are the First Wave of IGF-1R Antagonists for Cancer Therapy
At least six fully human or humanized antibodies against insulin-like growth factor-1 receptor (IGF-1R) are in early clinical development or close to phase I. - March 07, 2006
Dawn has Broken for Obesity Treatment with Cannabinoid Receptor (CB1) Antagonists
Tremendous impetus to discovery of novel CB1 antagonists by first-in-class CB1 receptor antagonist rimonabant under review by FDA and EMEA - February 22, 2006
Top 20 Biologics Now with Sales of US$ 37.7 Bln in 2005
The Top 20 blockbuster recombinant proteins and antibodies achieved record sales of US$ 37.7 bln in the year 2005 while combined sales of the 12 Top selling classes of recombinant proteins and antibodies reached the US$ 50 bln threshold. - February 15, 2006
Dosing Convenience Mandates the Pipeline of Glucagon-like Peptide-1 (GLP-1) Analogs for Type 2 Diabetes
Twice-daily injection is the benchmark set by exenatide, the first GLP-1 analog launched in the US by Lilly in June 2005 and half-year sales of US$ 74.6 mln, which now faces competition by GLP-1 analog treatment modalities with less frequent dosing. - February 07, 2006
Emerging Diabetes Drugs in Early Development
The complexity of glucose metabolism and the number of cellular processes affected by diabetes provides ample space for new drug targets and for first-in-class molecules. Some of them have reached or are close to early clinical development in type 2 diabetes. - January 31, 2006
High Interest in Inhibitors of the Novel Target Sodium-dependent Glucose (co-) Transporter (SGLT) for Therapy of Type 2 Diabetes
A plethora of SGLT inhibitors in the patent literature and seven compounds in early clinical development indicate an abundance of interest in the therapeutic use of SGLT inhibitors for the treatment of type 2 diabetes. SGLT inhibitors do not intervene with glucose metabolism, thus being complementary to mainstream approaches to glucose regulation, i.e. PPAR agonists, DPP-IV antagonists and GLP-1 analogues. - January 24, 2006
Cardiovascular safety determines the direction of PPAR agonist R&D
The two peroxisome proliferator-activated receptor (PPAR) gamma agonists pioglitazone and rosiglitazone approved for treatment of type 2 diabetes achieved combined 2004 global sales of US$ 3.96 bln shared between Takeda & Eli Lilly (52 %) and GlaxoSmithKline (48 %). - November 28, 2005
Competition is Needed in the Follicle Stimulating Hormone (FSH) Market
Ten years after the first approval of a recombinant human FSH for treatment of infertility the US$ 0.9 bln global market of recombinant human FSH (rhFSH) in 2004 was shared between Serono (63 % for follitropin alfa) and Organon (37 % for follitropin beta). - November 14, 2005